Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GPI-15715 Guilford.

Matthew D Krasowski1

  • 1Committee on Clinical Pharmacology & Pharmacogenomics and Department of Pathology, University of Chicago, Chicago, IL 60637, USA. kra3@harper.uchicago.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|January 29, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ADLM Guidance Document on Incorporating Gender Diversity in Pathology and Laboratory Medicine.

The journal of applied laboratory medicine·2026
Same author

ADLM Guidance Document on Laboratory Testing for Drugs of Misuse to Support the Emergency Department.

The journal of applied laboratory medicine·2026
Same author

Gender-Affirming Feminizing Hormone Therapy.

JAMA internal medicine·2025
Same author

Estradiol Concentrations for Adequate Gender-Affirming Feminizing Therapy: A Systematic Review.

LGBT health·2025
Same author

Laboratory Informatics Approaches to Improving Care for Gender- Diverse Patients.

Clinics in laboratory medicine·2024
Same author

SARS-CoV-2 seropositivity among healthcare professionals in a rural state.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2024
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Guilford is developing GPI-15715, a water-soluble propofol prodrug, as an anesthetic. Phase III trials are underway in the US to assess its sedative effects in various patient groups.

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Drug Development

Background:

  • Propofol is a widely used intravenous anesthetic agent.
  • Existing propofol formulations can cause pain on injection and have limited solubility.
  • GPI-15715 (PQ-1002, Aquavan) is a novel water-soluble prodrug of propofol.

Purpose of the Study:

  • To evaluate the sedative and anesthetic potential of GPI-15715.
  • To assess the safety and efficacy of GPI-15715 in diverse patient populations.
  • To compare GPI-15715 with existing anesthetic agents.

Main Methods:

  • Initiation of Phase III clinical trials in the United States in May 2004.
  • Evaluation of sedative effects in multiple patient cohorts.
  • Pharmacokinetic and pharmacodynamic assessments.

Related Experiment Videos

Main Results:

  • Data from Phase III trials are currently being collected and analyzed.
  • Preliminary findings on sedative efficacy and patient tolerance are anticipated.
  • Safety profiles and adverse event rates will be determined.

Conclusions:

  • GPI-15715 represents a promising advancement in anesthetic drug development.
  • Successful completion of Phase III trials could lead to a new anesthetic option.
  • Further research will elucidate the full clinical utility of this propofol prodrug.